Tollys appoints Amina Zinaï, MD, as head of clinical development
Calixar invests €1 Million in pipeline of highly druggable membrane protein targets and native antigens
Domain Therapeutics presents most recent developments of its BRET technology portfolio at AACR and ASPET events
Yposkesi accueille le groupe SK comme nouvel actionnaire majoritaire à son capital et noue ainsi un solide partenariat industriel de croissance
Yposkesi to give talk on gene therapy vectors at Virtual Cell & Gene Meeting on the Mediterranean, April 6 – 9, 2021
Cell-Easy strengthens executive team with two new highly experienced members
Seekyo raises over €650,000 from business angels and Bpifrance
Advent France Biotechnology appoints Alejo Chorny, PhD, as operating partner and head of new Spanish operations
AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial
• Investigational AELIX HTI vaccine leads to prolonged period without antiretroviral treatment (ART)
• Vaccine-induced immune T cell responses significantly correlate with prolonged time off ART
• Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication